Abstract: The invention provides human plasma-derived immunoglobulin compositions comprising low levels of thrombogenic agents and of IgG aggregates. The invention further provides methods for removing the active coagulation factors and IgG aggregates content of a plasma-derived immunoglobulin composition.

Abstract: The present invention disclosed methods for early intervention and prevention of the progression of pulmonary diseases, by administering alpha 1-antitrypsin (AAT) and particularly by administering AAT by inhalation.

Abstract: Methods for pre-emptive prophylactic treatment of graft versus host disease (GvHD) are disclosed. Such methods comprise the administration of Alpha-1 Antitrypsin (AAT) for pre-emption of GvHD.

Abstract: The present invention disclosed methods for suppressing or preventing an immune response to a specific antigen in a subject, comprising administering to the subject, the specific antigen by an intravenous route followed by an inhalation route.

Abstract: The present invention discloses methods for preventing or reducing lung injury associated with lung transplantation in lung transplant recipients. The method of the invention comprises the administration of improved dosage regimen of Alpha-1 Antitrypsin (AAT) for prevention of acute and/or chronic refractory rejection in lung transplant patients.

Abstract: The present invention provides compositions and methods for improving wound healing, reducing scar formation and/or promoting skin health and aesthetic appearance. In particular, the present invention provides protein compositions that are derived from Cohn fraction IV and/or IV-1 useful in promoting wound healing and for cosmetic care of the skin.

Abstract: Provided are methods for prevention or treatment of an infection caused by a virus of Flavivirus genus, and in particular by Zika virus disease in a mammalian fetus. An example for such a treatment is a passive immunization of the fetus by an antibody, and in particular a polyclonal antibody or a fragment thereof.

Abstract: The invention provides human plasma-derived immunoglobulin compositions comprising low levels of thrombogenic agents and of IgG aggregates. The invention further provides methods for removing the active coagulation factors and IgG aggregates content of a plasma-derived immunoglobulin composition.

Abstract: The present invention disclosed methods for early intervention and prevention of the progression of pulmonary diseases, by administering alpha 1-antitrypsin (AAT) and particularly by administering AAT by inhalation.

Abstract: The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases.

Abstract: The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha-1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation.

Abstract: A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to obtain pharmaceutical grade API on a commercial scale is provided. The API produced by the process is highly pure (at least 90% API out of the total protein) and highly active (at least 90% active API). Pharmaceutical compositions comprising the purified API and methods of using same are also described.

Abstract: The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases.

Abstract: A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to obtain pharmaceutical grade API on a commercial scale is provided. The API produced by the process is highly pure (at least 90% API out of the total protein) and highly active (at least 90% active API). Pharmaceutical compositions comprising the purified API and methods of using same are also described.

Abstract: The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical compositions comprising ultra transferrin alone as well as in the form of a conjugate.

Abstract: The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical compositions comprising ultra transferrin alone as well as in the form of a conjugate.